Compare Natera Inc. Common Stock (NTRA) vs Atlassian Corporation PLC (TEAM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Atlassian Corporation PLC — how do they compare? Natera Inc. Common Stock trades at $393.27 (market cap $57.03B), while Atlassian Corporation PLC trades at $204.54 (market cap $52.66B). The key difference: Natera Inc. Common Stock and Atlassian Corporation PLC are close in size by market cap, and Atlassian Corporation PLC is trading nearer its 52-week high, Natera Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Atlassian Corporation PLC for 65 Days on average.
| NTRA | TEAM | |
|---|---|---|
Market Cap | $57.03B | $52.66B |
Volume | 1,131,157 | 2,601,329 |
Sector | Health | Technology |
52-Week High | $425.64 | $208.04 |
52-Week Low | $179.42 | $57.15 |
Typical Hold Time | 0 Days | 65 Days |
Enterprise Value | $56.18B | $52.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Atlassian (TEAM) trades at $204.66, down 1.49% on the day, with a bullish technical signal from moving averages but overbought short-term RSI. The company shows strong revenue growth, improving net losses, and consistent earnings beats, though profitability metrics remain negative. Recent news highlights AI-driven growth catalysts and cloud momentum.
The outlook is positive given analyst consensus and AI adoption, but high valuation ratios and persistent net losses pose risks. Upside is supported by a large addressable market and subscription growth, while competition and execution challenges are key concerns for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Atlassian Corporation PLC
Atlassian produces software that helps teams work together more efficiently and effectively. The company provides project planning and management software, collaboration tools, and IT help desk solutions. The company operates in four segments: subscriptions (term licenses and cloud agreements), maintenance (annual maintenance contracts that provide support and periodic updates and are generally attached to perpetual license sales), perpetual license (upfront sale for indefinite usage of the software), and other (training, strategic consulting, and revenue from the Atlassian Marketplace app store). Atlassian was founded in 2002 and is headquartered in Sydney.
Read more on TEAM →
